Graves' orbitopathy;Endokrin orbitopathia

Orvosi Hetilap

Volumn 147, Issue 22, 2006, Pages 1011-1017

  Balázs, Csaba ^a,b  

^a Belgyógyászat Budapest ^*  (Hungary)

^b NONE   (Hungary)

Author keywords

Autoimmunity; Exogenic factors; Genetic factor; Graves' orbitopathy; Thyroid associated orbitopathy

Indexed keywords

AMINOGLYCOSIDE; AUTOANTIBODY; CYTOKINE; ETANERCEPT; GLITAZONE DERIVATIVE; GLUCOCORTICOID; GLUCOSE; IMMUNOGLOBULIN; IODINE; METHYLPREDNISOLONE; PENTOXIFYLLINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PLACEBO; PREDNISOLONE; RADIOACTIVE IODINE; SOMATOSTATIN DERIVATIVE; THYROTROPIN RECEPTOR ANTIBODY; TRIAMCINOLONE;

ARTICLE; AUTOIMMUNITY; CIGARETTE SMOKING; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE SEVERITY; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; ENDOCRINE OPHTHALMOPATHY; EPIDEMIOLOGICAL DATA; EXOPHTHALMOS; EXTRAOCULAR MUSCLE; EYE INFLAMMATION; FIBROBLAST; GENETIC SUSCEPTIBILITY; GRAVES DISEASE; HEREDITY; HUMAN; PATHOGENESIS; QUALITY OF LIFE; RISK FACTOR; SMOKING CESSATION; HYPERTHYROIDISM; PATHOPHYSIOLOGY; REVIEW;

GRAVES DISEASE; GRAVES OPHTHALMOPATHY; HUMANS; HYPERTHYROIDISM;

EID: 33748859904     PISSN: 00306002     EISSN: 17886120     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Alp, M. N., Ozgen, A., Can, I. és mtsai: Colour Doppler imaging of the orbital vasculature in Graves'disease with computed tomographic correlation. Br. J. Ophthalmol., 2000, 84, 1027-1030.
2. Balázs, Cs.: Pentoxiphylline in the management of Graves' orbital disease. In Thyroid Eye Disease, Szerk.: Dutton, M. D. Marcel Dekker Inc. New York. 2002, 443-449. old.
3. Balázs, Cs., Stenszky, V., Farid, N. R.: Association between Graves' ophthalmopathy and smoking. Lancet, 1990, 336, 754-755.
4. Balázs, C., Kiss, E., Vámos, A. és mtsa: Beneficial effect of pentoxifylline on thyroid associated ophthalmopathy (TAO): a pilot study. J. Clin. Endocrinol. Metab., 1997, 82, 1999-2002.
5. Balás, C., Kiss, E., Farid, N. R.: Inhibitory effect of pentoxyfilline on HLA-DR and glycosaminoglycan synthesis of retrobulbar fibroblasts induced by interleukin-1, tumor necrosis factor alpha and interferon gamma. Horm. Metab. Res., 1998, 30, 496-499.
6. Bartalena, L., Marcocci, C., Pinchera, A.: Graves'ophthalmopathy: a preventable disease? Eu. J. Endocrinol., 2002, 146, 457-461.
7. Bartalena, L., Tanda, M. L., Piantanida, E. és mtsai: Relationship between management of hyperthyroidism and course of the ophthalmopathy. J. Endocrinol. Invest., 2004, 3, 288-294.
8. Bartalena, L., Marcocci, C., Tanda, M. L. és mtsai: An update on medical management of Graves' ophthalmopathy. J. Endocrinol. Invest., 2005, 28, 469-478.
9. Bartley, G. B.: The epidemiology characteristics and clinical course of ophthalmopathy associated with autoimmune thyroid disease in Olmsted County, Minnesota. Trans. Am. Ophthalmol. Soc., 1998, 92, 477-588.
10. Berg, G., Andersson, T, Sjödell, L. és mtsai: Development of severe thyroid associated ophthalmopathy in a patient with disseminated thyroid cancer treated with recombinant human thyrotropin/radioiodine and retinoic acid. Thyroid, 2005, 15, 1389-1392.
11. Bonnema, S. J., Bartalena, L., Toft, A. D.: Controversies in radioiodine therapy: relation to ophthalmopathy, the possible radioprotective effect of antithyroid drugs, and use in large goitres. Eur. J. Endocrinol., 2002, 147, 1-11.
12. Cawood, T., Moriartry, P., O'Shea, D.: Recent development in thyroid eye disease. Brit. Med. J. 2004, 329, 385-390.
13. Charo, I. F., Ransohoff, R. M.: The many roles of chemokines and chemokine receptors in inflammation. N. Engl. J. Med., 2006, 354, 610-621.
14. Davies, T. F., Ando, T., Lin, R. és mtsai: Thyrotropin receptor-associated diseases: from adenomata to Graves' disease. J. Clin. Invest., 2005, 115, 1972-1983.
15. Ebner, R. M., Devoto, M. H., Weil, D. és mtsai: Treatment of thyroid associated ophthalmo-pathy with periocular injection of triamcinolone. Br. J. Ophthalmol., 2004, 11, 1359-1360.
16. Eckstein, A., Quadbeck, B., Mueller, G. és mtsai: Impact of smoking on the response to treatment of thyroid associated ophthalmopathy. Brit. J. Ophthalmol., 2003, 87, 773-776.
17. Egger, G., Liang, G., Aparicio, A. és mtsai: Epigenetics in human disease and prospects for epigenetic therapy. Nature, 2004, 429, 457-463.
18. Farid, N. R., Balazs, C.: The genetics of thyroid associated ophthalmopathy. Thyroid, 1998, 8, 407-409.
19. Finamor, F. E., Martins, J. R. M., Nakanami, D.: Pentoxifylline (PTX)- An alternative treatment in Graves' ophthalmopathy (inactive phase): Assessment by a disease specific quality of life questionnaire and by exophthalomometry in a prospective randomized trial. Eur. J. Ophthalmology., 2004, 14, 277-283.
20. Gogas, H.: Prognostic significance of autoimmunity during treatment of melanoma with interferon. N. Engl. J. Med., 2006, 354, 709-719.
21. Goh, M. S., Mab, A. A.: Orbital decompression in Graves'orbitopathy: efficacy and safety. Intern. Med. J., 2005, 35, 586-591.
22. Gupta, M. K., Perl, J., Beham, R. és mtsai: Effect of 131 iodine therapy on the course of Graves' ophthalmopathy: a quantitative analysis of extraocular muscle volumes using orbital magnetic resonance imaging. Thyroid, 2001, 11, 959-965.
23. Hatton, M. P., Rubin, P. A. D.: The pathophysiology of thyroid associated ophthalmopathy. Opthalmol. Clin. N. Am., 2002, 15, 113-119.
24. Kaczur, V., Puskás, L., Takács, M. és mtsai: Evolution of the thyrotropin receptor: a G protein coupled receptor with an intrinsic capacitiy to dimerize. Mol. Genet. Metab., 2003, 78, 275-290.
25. Kahaly, G. J., Forster, G., Hansen, C.: Glycosaminoglycans in thyroid eye disease. Thyroid 1998, 8, 429-432.
26. Kahaly, G. J., Rösler, H-P., Pitz, S. és mtsai: Low- versus high-dose radiotherapy for Graves' ophthalmopathy: a randomized, single blind trial. J. Clin. Endocrinol. Metab., 2000, 85, 102-108.
27. Kekow, J., Rheinhold, D., Pap, T. és mtsai: Intravenous immunoglobulins and transforming growth factor-β Lancet 1998, 351, 184-185.
28. Krassas, G. E., Doumas, A., Kaltsas, T. és mtsai: Somatostatin receptor scintigraphy before and after treatment with somatostatin analogues in patients with thyroid eye disease. Thyroid, 1999, 9, 47-52.
29. Krastinova-Lolov, D., Bach, C. A., Hartl, D. M. és mtsai: Surgical strategy in the treatment of globe protrusion depending on its mechanism (Graves'disease, nonsyndromic exoritism, or high myopia. Plast. Reconstr. Surg., 2006, 117, 553-564.
30. Kumar, S., Bahn, R. S.: Relative overexpression of macrophage-derived cytokines in orbital adipose tissue from patients with Graves' ophthalmopathy. J. Clin. Endocrinol. Metab., 2003, 88, 4246-4250.
31. Kurihara, H.: Total thyroidectomy for the treatment of hyperthyroidism in patients with ophthalmopathy. Thyroid, 2002, 12, 265-267.
32. Ludgate, M., Baker, G.: Inducing Graves' ophthalmopathy. J. Endocrinol. Inves., 2004, 27, 211-215.
33. Marino, M., Morabito, E., Altea, M. A. és mtsai: Autoimmun hepatitis during intravenous glucocorticoid pulse therapy for Graves' ophthalmopathy treated succesfully with glucocorticoid themselves. J. Indocrinol. Invest., 2005 3, 280-284.
34. Myliwiec, J., Kretowski, A., Staperin, A. és mtsa: Serum levels of soluble TNFalpha receptors (sTNFR1 and sTNFR2) during corticosteroid treatment in patients with Graves' ophthalmopathy. Immunol. Invest., 2004 33, 61-68.
35. Molnár, I., Kaczur, V., Boros, A. é mtsai: IgA autoantibodies against human eye muscle antigen detected by Western blotting and immunohistochemical methods in Graves' disease. J. Endocrinol. Invest., 1995, 18, 408-414.
36. Mourits, M. P., Prummel, M. F., Wiersinga, W. M., Koornnef, L.: Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy. Clin. Endocrinol. (Oxf.), 1997, 146, 751-757.
37. Német J., Tapasztó B., Tóth J. és mtsai: Szemészeti daganatok színkódolt ultrahang-vizsgálatának értékelése a szövettani eredmény tükrében. Magyar Onkológia, 2005, 49, 35-41.
38. Pasqual, D., Pierantoni, G. M., Fusco, A. és mtsai: Fenofibrate increases the expression of high mobility group AT-hook 2 (HMGA2) gene and induces adipocyte differentiation of orbital fibroblasts from Graves'ophthalmopathy. J. Mol. Endocrinol., 2004, 33, 133-143.
39. Perini, G., Tupler, R.: Altered gene silencing and human disease. Clin. Genet., 2006, 69, 1-7.
40. Perros, P., Kendall-Taylor, P., Neoh, C. és mtsai: A prospective study of the effects of radio-odine therapy for hyperthyroidism in patients with minimally active Graves' ophthalmopathy. J. Clin. Endocrinol. Metab., 2005, 90, 5321-5323.
41. Pinchera, A., Wiersinga, W., Glinoer, D. és mtsai: Classification of eye changes of Graves' disease. Thyroid, 1992, 2, 235-236.
42. Prabhakar, B. S., Bahn, R. S., Smith, T. J.: Current prespective on the pathogenesis of Graves' disease and ophthalmopathy. Endocrine Reviews, 2003, 24, 802 835.
43. Prummel, M. F., Bakker, A., Wiersinga, W. M.: Multi-center study on the characteristics and treatment strategies of patients with Graves'orbitopathy: the first European Group on Graves' orbitopathy experience. Eur. J. Endocrinol., 2003, 148, 491-495.
44. Shibayama, K., Ohyiama, Y., Yokota, Y. és mtsai: Assays for thyroid stimulating antibodies and thyrotropin inhibitory immunoglobulins in children with Graves' disease. Endocr. J., 2005, 52, 505-510.
45. Starkey, K., Heufelder, A., Baker, J. és mtsai: Peroxisome proliferator-activated receptor gamma in thyroid eye disease: contraindication for thiazolidine use? J. Clin. Endocrinol. Metab., 2003, 88, 55-59.
46. Stenszky, V., Kozma, L., Balázs, Cs. és mtsai: The genetics of Graves'disease: HLA and disease susceptibility. J. Clin. Endocrinol. Metab., 1985, 61, 735-740.
47. Szucs-Farkas, Zs., Tóth, J., Balázs, E. és mtsai: Using morphologic parameters of extraocular muscles for diagnosis and follow-up Graves' ophthalmopathy: diameters, areas or volume? Amer. J. Roentgenology, 2003, 179, 1005-1010.
48. Vaidya, B., Oakes, E. J., Imrie, H. és mtsai: CTLA4 gene and Graves' disease: association of Graves'disease with CTLA4 exon 1 and intron 1 polymorphisms, but not with the promoter polymorphism. Clin. Endocrinol. (Oxf.), 2003, 58, 732-735.
49. Valyasevi, R. W., Erickson, D. Z., Harteneck, D. A. és mtsai: Differentiation of orbital preadipocyte fibroblasts induces expression of functional thyrotropin receptor. J. Clin. Endocrinol. Metab., 1999, 84, 2557-2562.
50. Weber, K. J., Solorzano, K. J., Lee, J. K. és mtsai: Thyroidectomy remains an effective treatment option for Graves' disease. Am. J. Surg., 2006, 191, 400-405.
51. Wiersinga, W. M., Bartalena, L.: Epidemiology and prevention of Graves'ophthalmopathy. Thyroid, 2002, 12, 855-860.
52. Wiersinga, W. M.: The philosophy of Graves' ophthalmopathy. Orbit, 2005, 24, 165-171.
53. Yanik, B., Conkbayir, I., Acaroglu, G. és mtsai: Graves' ophthalmopathy: Comparison of Doppler sonography parameters with the clinical activity score. J. Clin. Ultrasound., 2005, 33, 375-380.
54. Yuen, N. C. M., Choi, K. L., Chan, M. K. és mtsai: Combined orbital irradiation and systemic steroids compared with systemic steroids alone in the management of moderate-to-severe Graves' ophthalmopathy: a preliminary study. Hong Kong Med. J., 2005. 11, 322-330.